Clinical characteristics and outcome of infective endocarditis among intravenous drug abusers in India

Abhishek Goyal a, Bishav Mohan a,*, Pawan Kumar b, Dinesh Gupta b, Rohit Tandon a, Sonaal Singla c, Gurbhej Singh a, Bhupinder Singh a, Shibba Takkar Chhabra a, Naved Aslam a, Gurpreet S. Wander b

a Department of Cardiology, Dayanand Medical College and Hospital, Unit Hero DMC Heart Institute, Ludhiana, India
b Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, India
c Dayanand Medical College and Hospital, Ludhiana, India

A R T I C L E   I N F O
Article history:
Received 23 July 2020
Accepted 14 September 2020
Available online 18 September 2020

Keywords:
Infective endocarditis
Intravenous drug abuse
India
Microbiological characteristics
Echocardiography

A B S T R A C T

Introduction: Infective endocarditis (IE) is the most dreaded complication of intravenous drug abuse (IVDA). IVDA is present in significant proportions in India. Since there is scarcity of Indian data on IVDA associated IE, we report a study comparing IVDA to non IVDA associated IE. We compare differences in clinical profile, microbiology, echocardiography and clinical outcome from a tertiary care hospital.

Methods: A total of 133 patients admitted from 1st January 2017 to 31st December 2019 who met the Modified Duke “definitive” criteria for IE were included. Detailed Information was collected regarding demography, clinical data and laboratory investigations. All patients underwent transthoracic echocardiography and trans-esophageal echocardiogram wherever necessary.

Results: Among a total of 133 patients, 54 patients (40.6%) were iv drug abusers. Patients in IVDA-group were younger, mostly males, more likely to have concomitant HCV and HIV infections compared to non IVDA-group. Chronic comorbidities such as DM and CKD were more common in non IVDA-group. Rate of positive blood culture was higher in IVDA-group compared to non IVDA-group (74.1% vs 32.9%, \( p < 0.001 \)) with different microbiological profile. Percentage of Methicillin resistant staphylococcus aureus (42.6% vs 17.7%, \( p = 0.003 \)) and pseudomonas related IE (18.5% vs 2.5%, \( p = 0.003 \)) was significantly higher among IVDA-group. IVDA-group most commonly had tricuspid valve involvement Whereas mitral and aortic valve were most commonly involved valve in non IVDA-group. Mortality was slightly higher among IVDA-group compared to non IVDA-group, though statistically non-significant. Left sided valve involvement and Congestive heart failure were independent predictors of mortality.

Conclusion: IVDA-IE is a significant problem in India. Demographic, microbiological and echocardiographic profile is quite different in IVDA and non IVDA-group. There is urgent need to conduct larger studies.

© 2020 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Infective endocarditis (IE) is primarily the infection of endocardium of heart affecting mainly heart valves. IE is still associated with very high morbidity and mortality despite various advances in diagnostic and treatment modalities.

There are various risk factors such as pre-existing valvular disease, congenital heart disease, intracardiac devices such as permanent pacemakers, prosthetic heart valves and surgical procedure related bacteraemia which predispose to IE.1 Intravenous drug abuse (IVDA) is an important risk factor as reported in various western studies.2,3 There is scarcity of Indian data on IVDA associated IE (IVDA-IE). This is due to the fact that the problem of IVDA among our population has been considered to be small in previous Indian studies.4,5 On the contrary, recent surveys show that IVDA is a significant problem in India specifically Punjab. According to a report published in 2019 by the ministry of social justice and empowerment, government of India, there are estimated 8.5 lakh intravenous drug abusers in India and Punjab has the second highest number among all the states.6 The Punjab Opioid
Dependence Survey has also found drug abuse to be a significant problem and has estimated the number of opioid dependent individuals in Punjab to be around 2.32 lakh and approximately one third of these individuals use intravenous (iv) route. In fact actual number is projected to be even higher.

Since there is limited data on IVDA-IE from India, we are reporting the study comparing IVDA to non IVDA-IE. We compare differences in clinical profile, microbiology, echocardiography and clinical outcome from a tertiary care referral hospital.

2. Methods

This study was carried out in a super specialty tertiary care referral hospital. This was an ambispective study including all the patients admitted with diagnosis of IE. Patients who met the Modified Duke “definitive” criteria for IE were included. Patients with possible IE were excluded. Patients were recruited retrospectively (n = 31) during the period from 1st January 2017 to 30th June 2018 and prospectively (n = 102) from 1st July 2018 to 31st December 2019. Retrospective data was obtained from the clinical records confirmed with investigations record obtained from echocardiography and microbiology department. Detailed Information was collected regarding demographic data, clinical data, and laboratory investigations including blood cultures. Transesophageal echocardiogram (TEE) was performed in patients with non-diagnostic TTE, suspected prosthetic valve endocarditis (PVE) and suspected cardiac mechanical complications.

The study was approved by the institutional ethical committee.

2.1. Statistical analysis

Data has been expressed as mean ± SE for quantitative variables and as frequency (%) for qualitative variables. Fisher exact test or Chi-square test was applied for comparison of categorical variables. t-test was applied for comparison of mean values. p < 0.05 was considered statistically significant. Univariate logistic regression analysis was carried out to assess the odds of factors associated with mortality. Variables which showed higher odds of mortality (p < 0.05) in the univariate analysis were included as independent variables for multivariable logistic regression analysis. Statistical analysis was conducted using Microsoft excel and windows based SPSS software (version 17.0).

3. Results

Baseline characteristics and predisposing conditions are shown in Table 1. Among a total of 133 patients, 54 patients (40.6%) were iv drug abusers. When comparing patients with IVDA to those without IVDA, they were younger. They were more likely to have concomitant HCV and HIV infections (Table 2). Other chronic comorbidities such as DM and CKD were more common in non-IVDA group. 98.1% of patients in IVDA-group were males as compared to 63.3% in non-IVDA group.

More than 50% of patients in non-IVDA group had predisposing cardiac conditions which were unlikely in IVDA group. Invasive procedure related infective endocarditis was also common in non-IVDA group.

Microbiological findings are shown in Table 2. Rate of positive blood culture was higher in IVDA compared to non IVDA group (74.1% vs 32.9%, p < 0.001). Causative microbiological agent differed significantly among two groups, as shown in Table 2.

Percentage of Methicillin resistant staphylococcus aureus (MRSA) related IE was significantly higher in IVDA compared to non IVDA group. Pseudomonas IE was also more common among IVDA compared to non IVDA group. Interestingly, none of our patients grew streptococcus viridians in blood culture.

Echocardiographic and laboratory findings are shown in Table 3. Multiple vegetations were observed in 5.3% of patients. IVDA group most commonly had tricuspid valve (TV) involvement compared to non IVDA group. Whereas mitral valve (MV) was the most commonly involved valve in non IVDA group compared to IVDA group.

There were no significant differences in terms of multi-valvular involvement, intra-cardiac complications (abscess perforation) and embolic events among two subgroups except for pulmonary infarct which was more common among IVDA group (Table 4).

Mortality was slightly higher among IVDA group compared to non IVDA group, though statistically non-significant (22.2% vs 17.7%, p = 0.520). Recurrent admissions (≥2 admissions) and need of surgery were also similar in two groups.

Table 3 shows regression analysis (univariate and multivariate) for predictors of mortality. Univariate analysis showed that Left sided valve involvement (MV, Aortic valve or both) had higher odds of mortality [odds ratio (OR) 3.39, 95% CI: 1.09–10.58; p = 0.028] compared to right sided valve involvement [TV, pulmonary valve (PV) or both]. Patients with congestive heart failure (CHF) were also at higher odds of mortality [OR 2.73, 95% CI: 1.14–6.56; p = 0.037]. Both left sided valve involvement (p = 0.008) and CHF (p = 0.003) were also independently associated with mortality on multivariate analysis also. Pseudomonal IE was associated with higher mortality on univariate analysis (OR 0.19, 95% CI: 0.06–0.68; p = 0.013) but adjusted odds ratio on multivariate analysis was not significant (p = 0.05).

4. Discussion

Drug addiction and IVDA is present in significant proportions in our country. Punjab is currently worst hit as large number of youths in productive age group of 18–35 years are affected. IVDA impacts all the aspects of health adversely, accounting for significant morbidity and mortality. IE is the most dreaded complication of IVDA. But IVDA-IE has never been reported in previous Indian studies. Since there is scarcity of Indian data, we are reporting a study on various aspects of IVDA-IE from a tertiary care referral centre. This study also compares IVDA with non IVDA-IE to shed light on differences in baseline characteristics, predisposing conditions, microbiology, echocardiographic patterns and outcomes from a tertiary care center in the current era.

Mean age of our population was 38.08 ± 14.73 years which is relatively young compared to most studies from developed countries. Most Indian studies from non IVDA-IE also reported a younger age of presentation which was primarily attributed to higher incidence of RHD. Whereas in the current study, young age of presentation is due to the fact that 40.6% of our subjects are iv drug abusers which affects mainly young population. Mean age was significantly lower among IVDA compared to Non IVDA-IE. Patients in IVDA-group were mostly males, more likely to have concomitant HCV and HIV infection. Similar observations have been reported from western literature also. A retrospective study from United States using national inpatient sample registry (2002–2016) found that patients in IVDA group were younger (median age, 38 versus 70 years; p < 0.001) and more commonly males (55.5% versus 50.8%; p < 0.001) compared to non IVDA group. They also had higher proportion of concomitant HCV and HIV infection.

Among predisposing conditions, IVDA commonly acted as a trigger for drug abuse— that looms over Indian population. Other predisposing conditions were uncommon and majority of the cases among IV drug abusers occurred in structurally normal valves. RHD accounted for only 9.0% of cases in
Table 1
Baseline characteristics, predisposing conditions and comorbidities according to drug abuse status.

| BASELINE CHARACTERISTICS                  | Total population (n = 133) | IVDA group (n = 54) | Non IVDA group (n = 79) | p VALUE        |
|-------------------------------------------|---------------------------|---------------------|-------------------------|----------------|
| Age (years)                               | 38.08 ± 14.73            | 29.39 ± 7.85        | 44.01 ± 15.41           | <0.001         |
| Male sex                                  | 103 (77.4%)              | 53 (98.1%)          | 50 (63.3%)              | <0.001         |
| HUMAN IMMUNODEFICIENCY VIRUS              | 3 (2.3)                  | 3 (5.6)             | 0                       | 0.065          |
| DIABETES MELLITUS                        | 20 (15.0)                | 0                   | 20 (25.3)               | 0.000          |
| CHRONIC KIDNEY DISEASE                   | 7 (5.3)                  | 0                   | 7 (8.9)                 | 0.041          |
| PREGNANCY                                 | 1 (0.8)                  | 0                   | 1 (1.3)                 | 0.407          |
| HEPATITIS C VIRUS                        | 34 (25.6)                | 28 (51.9)           | 6 (7.6)                 | <0.001         |
| MALIGNANCY                                | 1 (0.8)                  | 0                   | 1 (1.3)                 | 0.407          |
| PREDISPOSING CONDITIONS                   |                          |                     |                         |                |
| In hospital infection                     | 5 (3.8)                  | 0                   | 5 (6.3)                 | 0.080          |
| Invasive procedure related               | 23 (17.3)                | 1 (1.9)             | 22 (27.8)               | <0.001         |
| MITRAL VALVE PROLAPSE                    | 9 (6.8)                  | 1 (1.9)             | 8 (10.1)                | 0.083          |
| BICUSPID AORTIC VALVE                    | 4 (3.0)                  | 0                   | 4 (5.1)                 | 0.146          |
| degenerative Aortic valve disease        | 10 (7.5)                 | 0                   | 10 (12.7)               | 0.006          |
| RHEUMATIC HEART DISEASE                  | 12 (9.0)                 | 1 (1.9)             | 11 (13.9)               | 0.027          |
| VENTRICULAR SEPTAL DEFECT                | 3 (2.3)                  | 1 (1.9)             | 2 (2.5)                 | 0.795          |
| Device related (PACEMAKER/AICD)**        | 2 (1.5)                  | 0                   | 2 (2.5)                 | 0.239          |
| Prosthetic valve                         | 6 (4.5)                  | 0                   | 6 (7.6)                 | 0.081          |

Values are in mean ± SD or n(%).

* AICD: automated implantable cardioverter defibrillator.

Table 2
Microbial isolates according to drug abuse status.

|                  | Total population (n = 133) | IVDA group (n = 54) | Non IVDA group (n = 79) | p VALUE          |
|------------------|----------------------------|---------------------|-------------------------|-----------------|
| Staphylococci    |                            |                     |                         |                 |
| Viridans group   | 0                         | 0                   | 0                       |                 |
| Streptococcus    | 1 (0.8)                   | 0                   | 1 (1.3)                 | 0.407           |
| Enterococcus     | 4 (3.0)                   | 1 (1.9)             | 3 (3.8)                 | 0.646           |
| MRSA**           | 37 (27.8)                 | 23 (42.6)           | 14 (17.7)               | 0.003           |
| MSSA**           | 4 (3.0)                   | 3 (5.6)             | 1 (1.3)                 | 0.303           |
| Coagulase negative Staphylococcus | 0 | 0 | 0 | | |
| HACEK**          | 0                         | 0                   | 0                       |                 |
| Fungi            | 3 (2.3)                   | 2 (3.7)             | 1 (1.3)                 | 0.566           |
| E.coli/klebsiella| 4 (3.0)                   | 1 (1.9)             | 3 (3.8)                 | 0.646           |
| Pseudomonas      | 12 (9.0)                  | 10 (18.5)           | 2 (2.5)                 | 0.003           |
| Achromobacter    | 1 (0.8)                   | 0                   | 1 (1.3)                 | 0.407           |
| Culture positive | 66 (49.6)                 | 40 (74.1)           | 26 (32.9)               | <0.001          |
| Culture negative | 67 (50.4)                 | 14 (25.9)           | 53 (67.1)               | <0.001          |

Values are in n(%).

* Methicillin-resistant Staphylococcus aureus.
** Methicillin-sensitive Staphylococcus aureus.
* Haemophilus species, Aggregatibacter species, Cardio bacterium hominis, Eikenella corrodens, and Kingella.
Spanish intravenous drug abusers. In non IVDA-IE, MV and AV were most commonly involved. TV involvement was less common. This is similar to reports from various Indian & western studies.1,11–14

Out of various complications, pulmonary infarct was more common in IVDA-IE because of obvious reasons of pulmonary embolization of septic material from TV.

Overall mortality in our population was 19.5% with slightly higher mortality in IVDA (22.2%) compared to non-IVDA group (17.7%). This is considerably higher than western reports. In a recent study, IVDA-IE was associated with 6.8% index hospitalisation mortality. Also there was significantly less mortality (9.6%) among Non IVDA-IE in that study which is significantly less than our study. In our study, Higher mortality may be due to sicker

---

Table 3
Echocardiography and Laboratory Findings according to drug abuse status.

| ECHOCARDIOGRAPHIC FINDINGS | Total population (n = 133) | IVDA group (n = 54) | Non IVDA group (n = 79) | p VALUE |
|----------------------------|---------------------------|---------------------|-------------------------|---------|
| Mitral valve\(^a\)         | 55 (41.4)                 | 12 (22.2)           | 43 (54.4)               | <0.001  |
| Aortic valve               | 30 (22.6)                 | 5 (9.3)             | 25 (31.6)               | 0.003   |
| Tricuspid valve            | 47 (35.3)                 | 37 (68.5)           | 10 (12.7)               | <0.001  |
| Pulmonary valve            | 1 (0.7)                   | 0                   | 1 (1.3)                 | 0.407   |
| Multivalvular involvement  | 7 (5.3)                   | 1                   | 6                       | 0.240   |
| Prosthetic valve           | 6 (4.5)                   | 0                   | 6                       | 0.081   |

LABORATORY FINDINGS

| Low Hemoglobin (<12 gm%) | 114 (85.7) | 47 (87) | 67 (84.8) | 0.719 |
| Raised ESR (>20 mm)      | 112 (84.2) | 49 (90.7) | 63 (79.7) | 0.088 |
| Leucocytosis (>11,000/mm3) | 92 (69.2) | 43 (79.6) | 49 (62) | 0.036 |
| Leucopenia (<4000/mm3)   | 2 (1.5) | 0                   | 2(2.5) | 0.239 |
| Thrombocytopenia         | 43 (32.3) | 24 (44.4) | 19 (24.1) | 0.015 |
| Microscopic Haematuria   | 18 (13.5) | 7 (13) | 11 (13.9) | 0.874 |
| Elevated CRP             | 73 (54.9) | 30 (55.6) | 43 (64) | 0.156 |
| Positive rheumatoid Factor | 3 (2.3) | 0                   | 3 (3.8) | 0.147 |

Fever >38 C

130 (97.7) | 53 (98.1) | 77 (97.5) | 0.795 |

Values are in n(%).

\(^a\) Total number of all valves combined exceeds the total number of subjects because of multivalvular involvement.

---

Table 4
Complications and outcome according to drug abuse status.

| Echocardiography and Laboratory Findings | Total population (n = 133) | IVDA group (n = 54) | Non IVDA group (n = 79) | p VALUE |
|----------------------------------------|---------------------------|---------------------|-------------------------|---------|
| Intracardiac complications(abcess/perforation) | 8 (6.0) | 2 (3.7) | 6 (7.6) | 0.472 |
| Ischemic Stroke                        | 11 (8.3) | 4 (7.4) | 7 (8.9) | 0.765 |
| Embolisation, non stroke               | 26 (19.6) | 14 (25.9) | 12 (15.2) | 0.125 |
| Intracranial hemorrhage                | 3 (2.3) | 0                   | 3 (3.8) | 0.147 |
| New onset conduction abnormality       | 5 (3.8) | 0                   | 5 (6.3) | 0.117 |
| Pulmonary infarct                      | 12 (9.0) | 9 (16.7) | 3 (3.8) | 0.014 |
| Duration of stay (days)                | 14.4 ± 11.6 | 15.7 ± 14.5 | 13.6 ± 9.2 | 0.31 |
| Surgery                                | 15 (11.3) | 4 (7.4) | 11 (13.9) | 0.243 |
| Recurrent admissions(≥2 admissions)    | 33 (24.8) | 14 (25.9) | 19 (24.1) | 0.806 |
| Mortality                              | 26 (19.5) | 12 (22.2) | 14 (17.7) | 0.520 |

Values are in mean ± SD or n(%).

---

Table 5
Univariate and multivariate logistic regression analysis for factors associated with mortality (n = 26).

| Variable                          | Frequency(%) | Odds ratio (95% CI) | p-value | Adjusted Odds ratio (95% CI) | p-value |
|-----------------------------------|--------------|---------------------|---------|-----------------------------|---------|
| Age (Mean ± SD)                   | 35.62 ± 15.34 | 0.98 (0.95–1.01) | 0.344 | –                           | –       |
| Left sided valve involvement\(^a\) | 21 (84) | 3.39 (1.09–10.58) | 0.028 | 6.03 (1.62–22.53) | 0.008 |
| Leucocytosis (>11,000/mm3)        | 19 (73.1) | 1.26 (0.48–3.29) | 0.631 | –                           | –       |
| Deranged renal Function test      | 14 (53.8) | 1.74 (0.73–4.1) | 0.207 | –                           | –       |
| Deranged Liver Function test      | 12 (46.2) | 2.20 (0.92–5.29) | 0.075 | –                           | –       |
| Congestive heart failure          | 14 (53.8) | 2.73 (1.14–6.56) | 0.037 | 5.13 (1.74–15.14) | 0.003 |
| Septic pulmonary infectrat        | 2 (7.7) | 0.81 (0.16–3.94) | 0.792 | –                           | –       |
| septicecma                        | 22 (84.6) | 2.56 (0.82–8.01) | 0.097 | –                           | –       |
| Intracardiac complications        | 2 (7.7) | 1.40 (0.26–7.38) | 0.688 | –                           | –       |
| Intra venous drug abuse           | 12 (46.2) | 0.75 (0.32–1.79) | 0.520 | –                           | –       |
| MRESA\(^b\)                       | 7 (26.9) | 1.26 (0.48–3.29) | 0.631 | –                           | –       |
| Pseudomonas                       | 6 (23.1) | 0.19 (0.06–0.68) | 0.013 | 2.95 (0.77–11.23) | 0.113 |
| Multivalvular involvement         | 1 (3.8) | 1.48 (0.17–12.90) | 0.718 | –                           | –       |
| Surgical treatment                | 0           | 0                   | 0.042 | Went out of equation       |         |
| Ischemic Stroke                   | 4 (15.4) | 2.59 (0.69–9.65) | 0.224 | –                           | –       |

\(^a\) Mitral valve, aortic valve or both.

\(^b\) Methicillin-resistant Staphylococcus aureus.
patients, delay in seeking treatment and higher culture negativity rate. Higher frequency of virulent organisms such as pseudomonas may also be responsible.

On multivariate analysis, Left sided endocarditis and CHF were found to be independent predictors of mortality. This is in accordance with other reports which show that the mortality in left sided endocarditis is higher as compared to right sided endocarditis. Increased mortality in left sided endocarditis may be due to systemic embolization and CHF. It is well known that occurrence of CHF during the course of IE portends a bad prognosis.

To conclude, IVDA-IE is a significant problem in India associated with very high morbidity and mortality. The current study highlights important clinical, microbiological & echocardiographic aspects of IVDA-IE from India. Since there is limited data on IVDA-IE due to lack of Indian studies, there is a dire need to conduct larger prospective studies especially in regions with high IVDA incidence.

4.1. Study limitations

Our study has a few limitations. Firstly, it was a single center study. Being from a tertiary care center, the study also suffers from inherent referral and selection bias. Hence it may not represent the actual scenario in general population. We did not use any advanced serological and molecular technique for microbiological diagnosis.

Conflicts of interest

All authors have none to declare.

References

1. Math RS, Sharma G, Kothari SS, et al. Prospective study of infective endocarditis from a developing country. Am Heart J. 2011;162(4):633–638.
2. Kim JB, Ejiofor JI, Yammine M, et al. Surgical outcomes of infective endocarditis among intravenous drug users. J Thorac Cardiovasc Surg. 2016;152(3):832–841. e1.
3. Kadri AN, Wilner B, Hernandez AV, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019;8(19), e012969.
4. Grover A, Anand IS, Varma J, et al. Profile of right-sided endocarditis: an Indian experience. Int J Cardiol. 1991;33(1):83–88.
5. Raut N, Potdar A, Sharma S. Tricuspid valve endocarditis in non-drug abusers: a case series from India. Indian Heart J. 2018;70(4):476–481.
6. Ambekar A, Agrawal A, Rao R, et al. On Behalf of the Group of Investigators for the National Survey on Extent and Pattern of Substance Use in India. Magnitude of Substance Use in India. New Delhi: Ministry of Social Justice and Empowerment, Government of India; 2019 [cited 2020 June 20]. Available from: http://socialjustice.nic.in/writereaddata/UploadFile/Magnitude_Substance_Use_India_REPORT.pdf.
7. Punjab Opioid Dependence Survey (PODS), estimation of the size of opioid dependent population in Punjab, Brief Report. [cited 2020 September 25]. Available from: http://web.stanford.edu/~rm89/Punjab_AIMS_Report.pdf.
8. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–638.
9. Fernandes E, Olive C, Inamo J, et al. Infective endocarditis in French west indies: a 13-year observational study. Am J Trop Med Hyg. 2017;97(1):77–83.
10. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–473.
11. Senthilkumar S, Meson T, Subramanian G. Epidemiology of infective endocarditis in Chennai, South India. Indian J Med Sci. 2010;64(4):187–191.
12. Gupta A, Gupta A, Kaul U, et al. Infective endocarditis in an Indian setup: are we entering the ‘modern era? Indian J Crit Care Med. 2013;17(3):140–147.
13. Choudhury R, Grover A, Varma J, et al. Active infective endocarditis observed in an Indian hospital 1981-1991. Am J Cardiol. 1992;70:1453–1458.
14. Garg N, Kandpal B, Garg N, et al. Characteristics of infective endocarditis in a developing country: clinical profile and outcome in 192 Indian patients, 1992-2001. Int J Cardiol. 2005;98:253–260.
15. Loehey PA, LaSalvia MT, Rosenthal ES, et al. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infect Dis. 2019;6(4):ofz089.
16. Negi PC, Sondhi S, Asotra S, et al. Current status of rheumatic heart disease in India. Indian Heart J. 2019;71(1):85–90.
17. Karthikeyan G. Rheumatic heart disease in India: declining, but not fast enough. Natl Med J India. 2017;30(5):247–248.
18. Ramakrishnan S, Kothari SS, Bahl VK, et al. Prevalence of rheumatic heart disease: has it declined in India? Natl Med J India. 2009;22(2):72–74.
19. Subbaraju P, Rai S, Morakhia J, et al. Clinical - microbiological characterization and risk factors of mortality in infective endocarditis from a tertiary care academic hospital in Southern India. Indian Heart J. 2018;70(2):259–265.
20. Ghosh S, Sahoo R, Nath RK, et al. A study of clinical, microbiological, and echocardiographic profile of patients of infective endocarditis. IntSch Res Notices. 2014;2014:340601.
21. Padmaja K, Sudhabaran S, Vemul l, et al. Clinico microbiological spectrum of infective endocarditis - from a tertiary care centre in south India. Iran J Microbiol. 2017;9(5):257–263.
22. Slipcuk L, Cordolosa JN, Davila CD, et al. Infective endocarditis epidemiology over five decades: a systematic review [published correction appears in PLoS One. 2014;9(10), e115564, 2013;8(12):e22665.
23. Mirno J, Moreno A, Mestres CA. Infective endocarditis in intravenous drug abusers. Curr Infect Dis Rep. 2002;5(4):307–316.
24. Muñoz P, Kestler M, De Alarcon A, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Medicine (Baltim). 2015;94(43), e1816.
25. Rudasil SE, Sanainha Y, Mardock AL, et al. Clinical outcomes of infective endocarditis in injection drug users. J Am Coll Cardiol. 2019;73(5):559–570.